|
|
Volumn 30, Issue 5, 2012, Pages 373-374
|
|
Industry reels as Prometheus falls and Myriad faces further reviews.
a
a
NONE
|
|
Author keywords
[No Author keywords available]
|
|
Indexed keywords
DNA;
BIOTECHNOLOGY;
CHEMISTRY;
COMMERCIAL PHENOMENA;
DIAGNOSTIC TEST;
DRUG INDUSTRY;
HUMAN;
LEGAL ASPECT;
NOTE;
ORGANIZATION AND MANAGEMENT;
PATENT;
RESEARCH;
SWITZERLAND;
UNITED STATES;
BIOTECHNOLOGY;
COMMERCE;
DIAGNOSTIC TESTS, ROUTINE;
DNA;
DRUG INDUSTRY;
HUMANS;
PATENTS AS TOPIC;
RESEARCH;
SWITZERLAND;
UNITED STATES;
|
|
EID: 84864887573
PISSN: None
EISSN: 15461696
Source Type: Journal
DOI: 10.1038/nbt0512-373 Document Type: Note |
|
Times cited : (4)
|
|
References (0)
|
